DOYLESTOWN, Pa., March 30, 2020 — Diverse Biotech, Inc. www.diversebiotech.com has announced it has signed an initial partnership agreement with The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center to study its potential new therapeutic candidates in glioblastoma. The research will be performed in animal models of the disease to evaluate the...Read More
Doylestown, PA Nov. 5th 2019/– Diverse Biotech, Inc. has announced it has successfully synthesized its first three new chemical entities (NCEs) and have progressed them into the pre-clinical testing starting with in vitro testing. These NCEs will be targeting basal cell carcinoma, pancreatic cancer, and glioblastoma with the ultimate future goal of establishing new standards...Read More
Doylestown, PA Nov. 1st 2019/– Diverse Biotech, Inc. has announced it has opened its Headquarters at the Pennsylvania Biotechnology Center which is a prominent incubator for small growing life sciences companies in Doylestown, PA. The PA Biotechnology Center contains a wealth of resources and a core support group of scientists and executives motivated to work...Read More
Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.